Selskabets formål er at drive forskning, handel, fabrikation og dermed beslægtet virksomhed primært inden for medicinalbranchen.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 6.2 mia. | 1.4 mia. | 15 mia. | 12.9 mia. | 1795 | |
CVR: 16271187
Previous names: ApS KBUS 38 NR. 2520, BAVARIAN NORDIC RESEARCH INSTITUTEA/S
2 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 131 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Bavarian Nordic A/S demonstrates strong financial health, highlighted by a significant increase in revenue and profit in 2025, with revenue reaching 1.79 billion DKK and profit soaring to 1.09 billion DKK. The company has shown a positive trend, with revenue growing from 5.72 billion DKK in 2024 to 1.79 billion DKK in 2025, indicating robust demand for its pharmaceutical products. With equity of 13.16 billion DKK, Bavarian Nordic maintains a solid equity position, although the substantial drop in revenue from 2024 to 2025 raises concerns about sustainability. Overall, the company is well-positioned within the pharmaceutical manufacturing industry, benefiting from strong margins and a solid profit trajectory.
AI-generated summary
Companies in the same industry and area
CVR 33751540
CVR 37011185
CVR 29918791
CVR 32323502
CVR 32323537
Svend Andersen joined the board
Hans Martin Smith joined the board
Thomas Alex Bennekov joined the board
Karen Merete Jensen joined the board
Mathias Ulrich Grünfeld joined the board
Charl Gerhard Van Zyl joined the board
Sylwia Sokolowska joined the board
Maria Montserrat Montaner Picart left the board
Sylwia Sokolowska left the board
Britt Skaarup left the board
companydata.dk